DPP8 and cancer: It remains to be established whether compounds that, in addition to DPP-IV, inhibit other DPP-IV-like proteases, such as FAP, DPP8, and DPP9, may offer advantages over the use of more selective DPP-IV inhibitors in patients with cancer.